Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from Inmune Bio ( (INMB) ) is now available.
On June 26, 2025, INmune Bio Inc. announced it would host a conference call on June 30, 2025, to present top line data from its Phase 2 MINDFuL trial in early Alzheimer’s disease. The trial, involving patients with mild cognitive impairment and mild Alzheimer’s disease, evaluates the efficacy of XPro™, a next-generation inhibitor of tumor necrosis factor, in reducing neuroinflammation. The announcement could have significant implications for the company’s positioning in the biotechnology industry, particularly in the treatment of neurodegenerative diseases.
The most recent analyst rating on (INMB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.
Spark’s Take on INMB Stock
According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.
Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.
To see Spark’s full report on INMB stock, click here.
More about Inmune Bio
INmune Bio Inc. is a publicly traded clinical-stage biotechnology company focused on developing treatments targeting the innate immune system to combat diseases. The company has three product platforms: Dominant-Negative Tumor Necrosis Factor (DN-TNF) for treating mild Alzheimer’s disease, mild cognitive impairment, and treatment-resistant depression; the Natural Killer Cell Priming Platform for cancer treatment; and CORDStrom™, a stem cell platform for treating recessive dystrophic epidermolysis bullosa.
Average Trading Volume: 441,141
Technical Sentiment Signal: Sell
Current Market Cap: $171.1M
See more data about INMB stock on TipRanks’ Stock Analysis page.